home > ict > spring 2021 > ensuring data integrity with epro methods
International Clinical Trials

Ensuring Data Integrity with ePRO Methods

Ensuring data integrity during clinical trials is of the utmost importance. In the past few years, electronic patient-reported outcome (ePRO) approaches have been implemented to support these efforts, however, the pandemic has triggered a greater interest in wider deployment. The proliferation and acceptance of digital devices and wearables by regulators, clinicians, and patients has helped fuel this interest and highlighted the advantages of remote monitoring, helping bring clinical trials further into the modern age.

The 21st Century Cures Act and regulatory authorities, i.e., the MHRA and FDA, are embracing the need for more patient-centric drug development and wider access to ensure accurate data collection as trials become more decentralised. Decentralised clinical trials are defined as those executed through telemedicine and mobile/local healthcare providers using processes and technologies that differ from traditional clinical trial models.

For example, one of our partners is currently running 17 COVID-19 studies in ePRO. These studies are being conducted worldwide in more than 38 countries with sites of up to 400 and patient counts in the tens of thousands. Another partner is conducting 15 COVID-19 studies in ePRO. The adoption of these approaches certainly indicates that the market is confident in providing more patient-centric alternatives to the traditional trial model.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the Author

Sachin Bharadia is an Account Manager for the CRO PHASTAR. He has over 20 years’ experience in the pharmaceutical and CRO industry, alongside extensive experience of master data management, data lifecycle, and effective use of research data through biometrics and management and oversight of vendor relationships.

Print this page
Send to a friend
Privacy statement
News and Press Releases

Evonetix Commences Early Access Program for DNA Synthesised by Thermal Control on its Semiconductor Chip

Cambridge, UK 16th August 2022 – EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the opening of its early access program for semiconductor synthesised DNA. Evonetix’s DNA synthesis capability brings together patented semiconductor chip design and proprietary, thermally controlled synthesis chemistry, which will be integral to the Company’s future gene synthesis platforms.
More info >>

White Papers



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement